Financial Results Summary

Hemo Organic Limited submitted its unaudited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27).

Key Financial Figures (₹ in Lakhs):

  • Revenue from operations: ₹92.70 (Unaudited)
  • Other income: ₹0.19 (Unaudited)
  • Total Income: ₹92.90 (Unaudited)
  • Total Expenses: ₹7.42 (Unaudited)
  • Employee benefits expense: ₹1.36
  • Depreciation & amortization expense: ₹0.01
  • Other expenses: ₹6.05
  • Loss before tax: (₹7.42)
  • Tax expense: ₹0.00
  • Net Loss for the period: (₹7.42)
  • Total Comprehensive Income: (₹7.42)
  • Paid-up equity share capital: ₹346.59 (Face value ₹10 each)
  • Basic Earnings Per Share: (₹0.21)
  • Diluted Earnings Per Share: (₹0.21)

Comparative Figures:

  • Previous quarter (Q4 FY26, Audited): Net Loss of ₹50.57 lakh
  • Previous year same quarter (Q1 FY26, Unaudited): Net Loss of ₹8.57 lakh
  • Full year FY26 (Audited): Net Loss of ₹77.81 lakh

Auditor's Review Report

M/s. MAAK & Associates, Chartered Accountants (FRN: 135024W), conducted a limited review of the financial results as required by Regulation 33 of SEBI LODR.

Qualified Opinion: The auditor issued a qualified opinion stating: "We have not been provided with the balance confirmation or any other details for the trade receivable & trade payable in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transaction."

The review was conducted in accordance with Standard on Review Engagement (SRE) 2410 issued by ICAI. The auditor's report was signed by CA Kenan Satyawadi (Partner, Membership No.: 139533) on July 15, 2026, in Ahmedabad.

Preferential Issue of Convertible Warrants

Fund Utilization Status:

The company reported no deviations or variations in the utilization of proceeds from the preferential issue of convertible warrants for the quarter ended June 30, 2026.

Issue Details:

  • Date of allotment: February 26, 2026
  • Instrument: 34,00,000 convertible warrants
  • Issue price: ₹12.50 per warrant (including premium of ₹2.50)
  • Amount raised: ₹106.25 lakh (25% upfront receipt of total consideration)
  • Allottee category: Non-Promoter
  • Conversion terms: Each warrant convertible into one equity share of face value ₹10 each within 18 months from allotment date
  • Balance payable: ₹318.75 lakh (75% of issue price) payable at conversion

Utilization Details (₹ in Lakhs):

| Purpose | Original Allocation | Proportionate Allocation (25% Received) | Amount Utilized | Unutilized Amount |

| Working Capital Requirement | 318.75 | 79.69 | 79.69 | 0.00 |

| General Corporate Purpose | 106.25 | 26.56 | 25.71 | 0.85 |

| Total | 425.00 | 106.25 | 105.40 | 0.85 |

Governance and Approval

  • The financial results and fund utilization statement were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 15, 2026.
  • The company obtained a utilization certificate from M/s. MAAK & Associates, Chartered Accountants, confirming the fund utilization details.
  • The financial results were prepared in accordance with Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013.

Additional Information

  • The company's registered office is located at Shop 1 to 3, First floor, Piyu Apartment, Opp Electricity Sub Station, Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India - 382 350.
  • The company's CIN is L24231GJ1992PLC018224.
  • Previous period figures have been reclassified/regrouped wherever considered necessary to conform to current period presentation.